Mutations in the RAS (KRAS/NRAS) gene, found in approximately 10–30% of AML and 5–15% of MDS cases, facilitate the progression of MDS to AML and are associated with poor prognosis (106, 107). This evidence concerns the gene NRAS and myelodysplastic syndrome.